{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:05Z","timestamp":1794270125071,"version":"4.9.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107929","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:24:15Z","timestamp":1784388255000},"page":"107929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparator choice in Helicobacter pylori eradication: Tegoprazan-amoxicillin dual therapy vs. an optimised bismuth-containing quadruple therapy in a randomised trial and meta-analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"Miao","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhou","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunping","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-9695","authenticated-orcid":false,"given":"Yueyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9556-8771","authenticated-orcid":false,"given":"Xiuli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107929_bib0001","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/gutjnl-2021-325630","article-title":"Chinese consensus report on Family-based Helicobacter pylori infection control and management (2021 Edition)","volume":"71","author":"Ding","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0002","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day Vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13098","article-title":"Fourteen-day Tegoprazan-amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection (SHARE2301): a multicenter, noninferiority, randomized clinical trial","volume":"29","author":"Kong","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/1751-2980.13263","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: a systematic review and meta-analysis","volume":"25","author":"Wang","year":"2024","journal-title":"J Digest Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2026.107929_bib0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/apt.70535","article-title":"Review Article: Classic bismuth quadruple therapy for helicobacter pylori Infection-questions focused on clinical practice","volume":"63","author":"Gisbert","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70101","article-title":"Antibiotic combinations in bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and network meta-analysis","volume":"30","author":"Duan","year":"2025","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107325","article-title":"Antibiotic resistance of Helicobacter pylori in Mainland China: a focus on geographic differences through systematic review and meta-analysis","volume":"64","author":"Zeng","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0009","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s10620-024-08460-3","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized clinical trial of 10 and 14 days","volume":"69","author":"Ding","year":"2024","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0010","article-title":"Tegoprazan dual and quadruple therapy for Helicobacter pylori eradication: a prospective, randomized controlled trial in Beijing, China","volume":"12","author":"Cheng","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107929_bib0011","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.70180","article-title":"Fourteen-and ten-day tegoprazan-amoxicillin dual therapy vs. bismuth quadruple therapy for helicobacter pylori eradication-a noninferiority, multicenter, randomized controlled Trial","volume":"41","author":"Fan","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13151","article-title":"Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori eradication: a prospective, randomized, multicenter study in Fujian, China","volume":"29","author":"Lin","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0013","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000699","article-title":"Comparison of the efficacy between the dual therapy of Tegoprazan and the quadruple therapy of Tegoprazan: a randomized controlled multicenter study","volume":"15","author":"Liu","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251391276","article-title":"Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China","volume":"18","author":"Yang","year":"2025","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CM9.0000000000002565","article-title":"Dual therapy for Helicobacter pylori infection","volume":"136","author":"Duan","year":"2023","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70106","article-title":"Tegoprazan-based triple therapy for Helicobacter pylori eradication: a phase III multicenter randomized clinical trial","volume":"31","author":"Park","year":"2026","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0017","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2021.03.026","article-title":"Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship","volume":"20","author":"Graham","year":"2022","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterolog Associat"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0018","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002298","article-title":"It is time for a paradigm shift in design, execution, and publishing of comparative Helicobacter pylori treatment trials","volume":"118","author":"Graham","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102529","article-title":"10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial","volume":"70","author":"Yang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2026.107929_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2023.09.047","article-title":"Evolving concepts in Helicobacter pylori management","volume":"166","author":"Moss","year":"2024","journal-title":"Gastroenterology"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:37:26Z","timestamp":1794267446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002165"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107929","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparator choice in Helicobacter pylori eradication: Tegoprazan-amoxicillin dual therapy vs. an optimised bismuth-containing quadruple therapy in a randomised trial and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107929"}}